Boehringer Ingelheim invests €100 million: Expanded Respimat® production in Dortmund

Boehringer Ingelheim is investing more than €100 million at its Dortmund site to expand production capacity for the Respimat® inhaler to 44 million units per year. With this expansion, the research-driven pharmaceutical company is creating approximately 100 new jobs on site.

“The Respimat® is a success story – for Boehringer Ingelheim and for the patients,” explained Dr Wolfgang Baiker, member of the Board of Managing Directors at Boehringer Ingelheim responsible for Operations. “We want to continue this success story. The Respimat® inhaler will also in future be the inhalation device for applying our respiratory medications.”

The Boehringer Ingelheim microParts GmbH manufactures the innovative Respimat® inhaler in Dortmund for the global market.

In September 2004, Boehringer Ingelheim acquired the microtechnology company STEAG microParts GmbH and integrated it into the group. There are now more than 550 employees working at Boehringer Ingelheim microParts GmbH in Dortmund, where the Respimat® inhaler is produced.
At the company headquarters in Ingelheim, the inhalers are filled with the relevant active pharmaceutical ingredients and then distributed worldwide. Here, Boehringer Ingelheim is investing additional €72 million in the expansion of the Respimat® production.

The success of the inhaler is connected to its advanced technology. Without using propellants, the Respimat® inhaler generates a long-lasting fine mist that transports the active ingredient to the user’s lungs.

Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, Boehringer Ingelheim operates globally with 142 affiliates and a total of more than 47,400 employees. The focus of the family-owned company, founded in 1885, is researching, developing, manufacturing and marketing new medications of high therapeutic value for human and veterinary medicine.

Taking social responsibility is an important element of the corporate culture at Boehringer Ingelheim. This includes worldwide involvement in social projects, such as the initiative “Making more Health” and caring for the employees. Respect, equal opportunities and reconciling career and family form the foundation of the mutual cooperation. In everything it does, the company focuses on environmental protection and sustainability.

In 2013, Boehringer Ingelheim achieved net sales of about 14.1 billion euros. R&D expenditure corresponds to 19.5% of its net sales.